rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2011-7-2-199-203rpcardio-750Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯPATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSIONПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ И ПРИНЦИПЫ ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ ТРОМБОЭМБОЛИЧЕСКОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИШостакН. А.ShostakN. A.

д.м.н., профессор, заведующая кафедрой факультетской терапии им. акад. А.И. Нестерова лечебного факультета

КлименкоА. А.KlimenkoA. A.

к.м.н., доцент кафедры факультетской терапии им. акад. А.И. Нестерова лечебного факультета

ДемидоваН. А.DemidovaN. A.

ассистент кафедры факультетской терапии им. акад. А.И. Нестерова лечебного факультета

ntverdova@yandex.ruНовиковИ. В.NovikovI. V.

аспирант кафедры факультетской терапии им. акад. А.И. Нестерова лечебного факультета

Российский государственный медицинский университетРоссияRussian State Medical UniversityRussian Federation20111401201672199203Copyright © Shostak N.A., Klimenko A.A., Demidova N.A., Novikov I.V., 20162016Шостак Н.А., Клименко А.А., Демидова Н.А., Новиков И.В.Shostak N.A., Klimenko A.A., Demidova N.A., Novikov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/750

Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications, results, limitations for CTPH surgical treatment are shown. Data of the currently completed clinical studies on bosentan, prostacyclin analogues and phosphodiesterase-5 inhibitors usage in CTPH are presented.

Представлены данные о частоте развития хронической тромбоэмболической легочной гипертензии (ХТЛГ). Описаны основные клинические проявления ХТЛГ. Освещены возможные причины и патогенетические механизмы формирования ХТЛГ , описаны маркеры неблагоприятного течения заболевания. Рассмотрены показания, результаты, ограничения к проведению хирургического лечения ХТЛГ . Приведены данные последних клинических исследований, посвященных применению бозентана, аналогов простациклина, ингибиторов фосфодиэстеразы-5 при этом тяжелом заболевании.

легочная гипертензияхроническая тромбоэмболическая легочная гипертензиятромбоэмболия легочной артериитромбэндартерэктомиябозентананалоги простациклинаингибиторы фосфодиэстеразы-5pulmonary hypertensionchronic thromboembolic pulmonary hypertensionthromboembolism of pulmonary arterythromboendarterectomybosentanprostacyclin analoguesphosphodiesterase-5 inhibitorsReferencesMagidson O., Jabson G. Trombosis of the main pulmonary arteries. Br Heart J 1955; 17: 207-218Magidson O., Jabson G. Trombosis of the main pulmonary arteries. Br Heart J 1955; 17: 207-218Gibbon JH. Jr., Hopkinson M., Churchill E.D. Changes in the circulation produced by gradual occlusion of the pulmonary artery. J Clin Invest 1932; 11(3):543–553Gibbon JH. Jr., Hopkinson M., Churchill E.D. Changes in the circulation produced by gradual occlusion of the pulmonary artery. J Clin Invest 1932; 11(3):543–553Dentali F., Donadini M., Gianni M. et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009; 124(3):256-258Dentali F., Donadini M., Gianni M. et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009; 124(3):256-258Savel'ev V.S., editor. Phlebology. Guide for Physicians. M.: Meditsina; 2001. Russian (Са-вельев В.С., редактор. Флебология. Руководство для врачей. М.: Медицина; 2001)Savel'ev V.S., editor. Phlebology. Guide for Physicians. M.: Meditsina; 2001. Russian (Са-вельев В.С., редактор. Флебология. Руководство для врачей. М.: Медицина; 2001)Fedullo P.F., Auger W.R., Channick R.N. et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 1995;16:353–374Fedullo P.F., Auger W.R., Channick R.N. et al. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 1995;16:353–374Riedel M., Stanek V., Widimsky J., Prerovsky I. Longterm Follow-up of Patients with Pulmonary Thromboembolism. Chest 1982;81;151-158Riedel M., Stanek V., Widimsky J., Prerovsky I. Longterm Follow-up of Patients with Pulmonary Thromboembolism. Chest 1982;81;151-158Grifoni S., Olivotto I., Cecchini P. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101(24):2817-22Grifoni S., Olivotto I., Cecchini P. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101(24):2817-22Tunariu N., Gibbs SJ., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-684Tunariu N., Gibbs SJ., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-684Galiè N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537Galiè N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537Torbicki A. Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. Rev Esp Cardiol 2010;63(7):832-849Torbicki A. Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. Rev Esp Cardiol 2010;63(7):832-849Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637-648Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637-648Wolf M., Boyer-Neumann C., Parent F. et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395–399Wolf M., Boyer-Neumann C., Parent F. et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395–399Arnoni R.T., Jatene F.B., Bernardo W.M. et al. Medial hypertrophy in patients with pulmonary embolism: anatomopathological study. Arq Bras Cardiol 2007;88(6):660-666Arnoni R.T., Jatene F.B., Bernardo W.M. et al. Medial hypertrophy in patients with pulmonary embolism: anatomopathological study. Arq Bras Cardiol 2007;88(6):660-666Roytberg G.E., Strutynskiy A.V. Internal medicine. Circulatory system. M.: Binom; 2003. Russian (Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система. М.: Бином; 2003).Roytberg G.E., Strutynskiy A.V. Internal medicine. Circulatory system. M.: Binom; 2003. Russian (Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система. М.: Бином; 2003).Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237Bauer M., Wilkens H., Langer F. et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036Bauer M., Wilkens H., Langer F. et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-1036Humbert M., Morrell N.W., Archer S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13–24Humbert M., Morrell N.W., Archer S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13–24Reesink H.J., Meijer R.C., Lutter R. et al. Hemodynamic and Clinical Correlates of Endothelin-1 in Chronic Thromboembolic Pulmonary Hypertension. Circ J 2006; 70: 1058-1063Reesink H.J., Meijer R.C., Lutter R. et al. Hemodynamic and Clinical Correlates of Endothelin-1 in Chronic Thromboembolic Pulmonary Hypertension. Circ J 2006; 70: 1058-1063Dentali F., Donadini M., Gianni M. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med. 2009; 4(2): 123-128Dentali F., Donadini M., Gianni M. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med. 2009; 4(2): 123-128Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402 -1412Mukoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402 -1412Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129(5):1313-1321Fijalkowska A., Kurzyna M., Torbicki A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129(5):1313-1321Donadini M., Dentali F., Ageno W. Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. Intern Emerg Med 2009;4:441-442Donadini M., Dentali F., Ageno W. Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. Intern Emerg Med 2009;4:441-442Reesink H.J., Tulevski I.I., Marcus J.T. et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84(2):537-43Reesink H.J., Tulevski I.I., Marcus J.T. et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84(2):537-43Von Haehling S., von Bardeleben R.S., Kramm T. et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2010;144(2):206-11.Von Haehling S., von Bardeleben R.S., Kramm T. et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2010;144(2):206-11.Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clinica Chimica Acta 2005;352:15-35Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clinica Chimica Acta 2005;352:15-35Haltern G., Peiniger S., Bufe A. et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Car-diol 2010;105(1):1-9Haltern G., Peiniger S., Bufe A. et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Car-diol 2010;105(1):1-9Puls M., Dellas C., Lankeit M. et al. Heart-type fatty acidbinding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007;28:224-229Puls M., Dellas C., Lankeit M. et al. Heart-type fatty acidbinding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007;28:224-229Orfanos S.E., Zakynthinos S. Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein. Eur Respir J 2008;31:915-917Orfanos S.E., Zakynthinos S. Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein. Eur Respir J 2008;31:915-917Lankeit M., Dellas C., Panzenbock A. et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2008;31:1024-1029Lankeit M., Dellas C., Panzenbock A. et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2008;31:1024-1029Hollister L., Cull V. The syndrome of chronic thrombosis of the major pulmonary arteries. American Journal of Medicine 1956;21:312—320Hollister L., Cull V. The syndrome of chronic thrombosis of the major pulmonary arteries. American Journal of Medicine 1956;21:312—320Savel'ev B.C., Yablokov E.G., Kirienko A.I. Massive pulmonary thromboembolism. M: Med-itsina; 1990. Russian (Савельев B.C., Яблоков Е.Г., Кириенко А.И. Массивная тром-боэмболия легочной артерии. М: Медицина; 1990)Savel'ev B.C., Yablokov E.G., Kirienko A.I. Massive pulmonary thromboembolism. M: Med-itsina; 1990. Russian (Савельев B.C., Яблоков Е.Г., Кириенко А.И. Массивная тром-боэмболия легочной артерии. М: Медицина; 1990)Keogh A., Mayer E., Benza R. et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009;54:S67–S77Keogh A., Mayer E., Benza R. et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009;54:S67–S77Wittine L.M., Auger W.R. Chronic Thromboembolic Pulmonary Hypertension. Curr Treat Options Cardiovasc Med 2010;12(2):131–141Wittine L.M., Auger W.R. Chronic Thromboembolic Pulmonary Hypertension. Curr Treat Options Cardiovasc Med 2010;12(2):131–141Condliffe R., Kiely D.G., Gibbs S.R. et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Resp Crit Care Med 2008;177:1122–1127Condliffe R., Kiely D.G., Gibbs S.R. et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Resp Crit Care Med 2008;177:1122–1127Corsico A.G., D’Armini A.M., Cerveri I. et al. Long-term outcome after pulmonary en-darterectomy. Am J Respir Crit Care Med 2008;178:419–424Corsico A.G., D’Armini A.M., Cerveri I. et al. Long-term outcome after pulmonary en-darterectomy. Am J Respir Crit Care Med 2008;178:419–424Ono F., Nagaya N., Okumura H. et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123(5):1583—1588Ono F., Nagaya N., Okumura H. et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003; 123(5):1583—1588Lapina T.V., Vishnevskiĭ A.A. Methods of treatment of chronic thromboembolic pulmonary hypertension. Khirurgiya. Zhurnal im. N.I. Pirogova 2007; 4:58—61. Russian (Лапина Т.В., Вишневский А.А. Методы лечения хронической тромбоэмболической легочной гипертензии. Хирургия. Журнал им. Н.И. Пирогова 2007; 4:58—61)Lapina T.V., Vishnevskiĭ A.A. Methods of treatment of chronic thromboembolic pulmonary hypertension. Khirurgiya. Zhurnal im. N.I. Pirogova 2007; 4:58—61. Russian (Лапина Т.В., Вишневский А.А. Методы лечения хронической тромбоэмболической легочной гипертензии. Хирургия. Журнал им. Н.И. Пирогова 2007; 4:58—61)Jamieson S., Kapelanski D., Sakakibara N. et al. Pulmonary endarterectomy: experience and lessons learned in 1, 500 cases. Ann Thorac Surg 2003;76:1457–1464Jamieson S., Kapelanski D., Sakakibara N. et al. Pulmonary endarterectomy: experience and lessons learned in 1, 500 cases. Ann Thorac Surg 2003;76:1457–1464Bresser P., Pepke-Zaba J., Jais X. et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006;3:594–600Bresser P., Pepke-Zaba J., Jais X. et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006;3:594–600Galiè N., Palazzini M., Leci E., Manes A. Current Therapeutic Approaches to Pulmonary Arterial Hypertension Rev Esp Cardiol 2010;63(6):708-724Galiè N., Palazzini M., Leci E., Manes A. Current Therapeutic Approaches to Pulmonary Arterial Hypertension Rev Esp Cardiol 2010;63(6):708-724Bonderman D., Jakowitsch J., Adlbrecht C. et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005;93:512-516Bonderman D., Jakowitsch J., Adlbrecht C. et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005;93:512-516Mayer E., Kramm T., Dahm M. et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Acta Chirurgica Austriaca 1999;31:308—331Mayer E., Kramm T., Dahm M. et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Acta Chirurgica Austriaca 1999;31:308—331Auger W.R., Fedullo P.F. Chronic thromboembolic pulmonary hypertension. Sem Resp Crit Care Med. 2009;30:471–483Auger W.R., Fedullo P.F. Chronic thromboembolic pulmonary hypertension. Sem Resp Crit Care Med. 2009;30:471–483Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-781Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-781Reichenberger F., Voswinckel R., Enke B. et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Resp J 2007;30:922–927Reichenberger F., Voswinckel R., Enke B. et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Resp J 2007;30:922–927Hughes R.J., Jais X., Bonderman D. et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Resp J 2006;28:138–143Hughes R.J., Jais X., Bonderman D. et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Resp J 2006;28:138–143Cabrol S., Souza R., Jais X. et al. Intravenous epoprostenol in inoperable chronic thromboembolic disease. J Heart Lung Transplant 2007;26:357–362Cabrol S., Souza R., Jais X. et al. Intravenous epoprostenol in inoperable chronic thromboembolic disease. J Heart Lung Transplant 2007;26:357–362Reesink H.J., Surie S., Kloek J.J. et. аl. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary. J Thorac Cardiovasc Surg 2010; 139(1):85-91Reesink H.J., Surie S., Kloek J.J. et. аl. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary. J Thorac Cardiovasc Surg 2010; 139(1):85-91Jais X., D’Armini A., Jansa P. et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2008;52:2127–2134Jais X., D’Armini A., Jansa P. et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2008;52:2127–2134Wharton J., Strange J.W., Moller G.M. et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172:105–113Wharton J., Strange J.W., Moller G.M. et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172:105–113Suntharalingam J., Treacy C., Doughty N. et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134;229-236Suntharalingam J., Treacy C., Doughty N. et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134;229-236Badesch D.B., Hill N.S., Burgess G. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-2422Badesch D.B., Hill N.S., Burgess G. et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-2422Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle tell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-896Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle tell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-896Nagaya N., Sasaki N., Ando M. et al. Prostacyclin therapy before pulmonary thromboendarterec tomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343Nagaya N., Sasaki N., Ando M. et al. Prostacyclin therapy before pulmonary thromboendarterec tomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338–343Skoro-Sajer N., Bonderman D., Wiesbauer F. et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483–489Skoro-Sajer N., Bonderman D., Wiesbauer F. et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483–489Krug S., Hammerschmidt S., Pankau H. et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008;76:154–159Krug S., Hammerschmidt S., Pankau H. et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008;76:154–159Kramm T., Eberle B., Krummenauer F. et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003;76(3):711-718Kramm T., Eberle B., Krummenauer F. et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003;76(3):711-718Kerr K.M., Rubin L.J. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest 2003;123:319–320Kerr K.M., Rubin L.J. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest 2003;123:319–320

The authors declare that there are no conflicts of interest present.